AuthorsNeary, Peter M
Wang, Jiang H
Pfirrmann, Rolf W
Bouchier-Hayes, David J
Redmond, Henry P
AffiliationDepartment of Academic Surgery, University College Cork, Cork University Hospital, Wilton, Cork, Ireland. email@example.com
MetadataShow full item record
CitationThe evolving role of taurolidine in cancer therapy. 2010, 17 (4):1135-43 Ann. Surg. Oncol.
JournalAnnals of surgical oncology
AbstractBACKGROUND AND DESIGN: Taurolidine consists of two taurinamide rings derived from the naturally occurring amino acid taurine. It has been utilized to prevent adhesions, as an antimicrobial, and as an anti-inflammatory agent. More recently, it has been found to exert antineoplastic activity. We reviewed the literature regarding taurolidine and its role in cancer treatment. RESULTS AND CONCLUSION: Taurolidine induces cancer cell death through a variety of mechanisms. Even now, all the antineoplastic pathways it employs are not completely elucidated. It has been shown to enhance apoptosis, inhibit angiogenesis, reduce tumor adherence, downregulate proinflammatory cytokine release, and stimulate anticancer immune regulation following surgical trauma. Apoptosis is activated through both a mitochondrial cytochrome-c-dependent mechanism and an extrinsic direct pathway. A lot of in vitro and animal data support taurolidine's tumoricidal action. Taurolidine has been used as an antimicrobial agent in the clinical setting since the 1970s and thus far appears nontoxic. The nontoxic nature of taurolidine makes it a favorable option compared with current chemotherapeutic regimens. Few published clinical studies exist evaluating the role of taurolidine as a chemotherapeutic agent. The literature lacks a gold-standard level 1 randomized clinical trial to evaluate taurolidine's potential antineoplastic benefits. However, these trials are currently underway. Such randomized control studies are vital to clarify the role of taurolidine in modern cancer treatment.
- The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
- Authors: Marley K, Helfand SC, Edris WA, Mata JE, Gitelman AI, Medlock J, Séguin B
- Issue date: 2013 Jan 18
- Treatment of glioblastoma with intravenous taurolidine. First clinical experience.
- Authors: Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Jänisch W, Brock M
- Issue date: 2004 Mar-Apr
- Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
- Authors: Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S
- Issue date: 2007 Jun
- The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma.
- Authors: Nici L, Monfils B, Calabresi P
- Issue date: 2004 Nov 15
- Enhancement of Fas-ligand-mediated programmed cell death by taurolidine.
- Authors: Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Möhler H
- Issue date: 2003 May-Jun